Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on January 16th, 2023%
A vaccine against gonorrhea given as a nasal spray is shown to generate protective immune responses in lab mice of both sexes, and in females similar to an intravaginal vaccine. . . . → Read More: Nasal Spray Vaccine Shown to Stop Gonorrhea Infections
By Alan, on January 13th, 2023%
A new company developing diagnostics for neurological and other disorders based on environmental exposures is raising $16 million in venture funds. . . . → Read More: Environmental Biomarker Start-Up Gains $16M in Early Funds
By Alan, on December 30th, 2022%
A new enterprise is formed to develop gene-editing therapies for mitochondrial disorders, rare inherited mutations in the energy centers of cells. . . . → Read More: Company Started for Gene Editing Rare Inherited Diseases
By Alan, on December 27th, 2022%
A discoverer of therapeutic peptides signed licensing deals in the past few days with two drug makers that could bring the company as much as $3.3 billion. . . . → Read More: Peptide Discovery Company to Gain $3.3B in Licensing Deals
By Alan, on December 7th, 2022%
A technology investment company is partnering with a Silicon Valley incubator program to support start-up businesses developing new types of semiconductors. . . . → Read More: Venture Investor to Back Semiconductor Start-Ups
By Alan, on November 17th, 2022%
A developer of cancer treatments triggered by tumor chemistry is partnering with biologic drug maker Regeneron on dual-action cancer immunotherapies. . . . → Read More: Biotech, Regeneron in $2B Cancer Antibody Deal
By Alan, on November 15th, 2022%
A start-up enterprise seeks to make drugs for treating rare diseases more readily available to physicians and patients in Europe. . . . → Read More: Company to Boost Orphan Drugs in Europe
By Alan, on November 8th, 2022%
Developers of a patch with tiny needles instead of a syringe to deliver vaccines say a clinical trial testing a Covid-19 patch is now underway in Australia. . . . → Read More: Covid-19 Vaccine Patch Clinical Trial Begins
By Alan, on October 20th, 2022%
A clinical trial is underway testing a synthetic antibody designed to prevent SARS-CoV-2 viral infections in people with compromised immune systems. . . . → Read More: Trial in Progress of Antibody Blocking Covid-19 in Immunocompromised
By Alan, on October 10th, 2022%
A company making precision therapies for neurological disorders is acquiring rights to a compound first designed as a treatment for cancer, inflammation, and oxidative stress. . . . → Read More: Drug Licensed for Precision Autism Spectrum Therapies
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|